Samsung Biologics Participates in PEGS Boston in the US

Expanding CDO Client Engagement Through Business Meetings and More

Samsung Biologics announced on May 13 that it participated in the Protein Engineering & Antibody Engineering Summit (PEGS Boston), a global biopharmaceutical technology conference. At this event, Samsung Biologics showcased its outstanding contract development (CDO) capabilities, including high-concentration formulation drug development and candidate feasibility evaluation.

Heonchang Lim, Head of Formulation Development Group at Samsung Biologics CDO Development Center, is introducing the development feasibility evaluation platform 'DEVELOPICK™' at PEGS Boston held in Boston, Massachusetts, USA on the 12th. Samsung Biologics

PEGS Boston is the world’s largest protein and antibody therapeutics conference, bringing together more than 2,400 participants to discuss the latest biopharmaceutical technologies. It is held annually in May in Boston, Massachusetts, and this year the event runs for five days from May 12 to 16 (local time). At this year’s event, Samsung Biologics set up a dedicated meeting room and focused on expanding its connections with major clients by holding business meetings with global pharmaceutical companies.

On the first day of the event, May 12, Samsung Biologics hosted a luncheon presentation on the theme “Streamlining Drug Development: From Feasibility Assessment to High-Concentration Formulation Development.” Heonchang Lim, Head of the Formulation Development Group at the CDO Development Center, introduced Samsung Biologics’ key CDO services, including the high-concentration formulation drug development platform “S-HiCon™” and the feasibility evaluation platform “DEVELOPICK™.”

S-HiCon is a platform that leverages Samsung Biologics’ extensive formulation development experience to support clients in developing ultra-high-concentration formulations, and was first unveiled in October 2024. High-concentration formulation drugs are attracting attention because they reduce the burden on patients during administration and lower storage and transportation costs.

DEVELOPICK is a feasibility evaluation platform that has been continuously improved since its initial launch in October 2022, and is now in version 3.0. It helps identify optimal drug candidates by evaluating the properties of substances with only small amounts of protein at the drug discovery stage.

Samsung Biologics currently possesses nine CDO-related technology platforms. In addition to S-HiCon and DEVELOPICK, these include: the proprietary cell line platform “S-CHOice®”; the bispecific antibody platform “S-DUAL™”; the candidate substance transient expression platform “S-CHOsient™”; the analytics-based substance support platform “S-Glyn™”; the high-concentration biopharmaceutical development support platform “S-Tensify™”; the afucosylation cell line platform “S-AfuCHO™”; and the protein charge variant control platform “S-Opticharge™.” These platforms enable Samsung Biologics to provide customized CDO services from early development through Investigational New Drug (IND) application stages.

Meanwhile, Samsung Biologics is expanding its engagement with global clients and potential customers by participating in various international conferences this year. In January, the company attended the JP Morgan Healthcare Conference, and in March, it met with a range of clients at events such as Decat Week. Next month, Samsung Biologics plans to participate in the world’s largest bio-pharmaceutical exhibition, the 2025 BIO International Convention (BIO USA), to be held in Boston, USA.